Atrioventricular block

disease

On this page

Also known as atrioventricular block (disease)AV blockAV nodal blockAVB

Summary

Atrioventricular block (MONDO:0000465) is a disease caused by variants in DES and LMNA, with 3 cohort genes (15 GWAS associations across 16 studies) and 72 clinical trials. Top therapeutic interventions include adenosine and methoprene.

At a glance

Causal genes: DES (GenCC Strong), LMNA (GenCC Strong)
Cohort genes: 3
GWAS associations: 15
ClinVar variants: 2
Clinical trials: 72

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	atrioventricular block
Mondo ID	MONDO:0000465
MeSH	D054537
DOID	DOID:0050820
SNOMED CT	233917008
UMLS	C0004245
MedGen	13956
Is cancer (heuristic)	no

Also known as: atrioventricular block · atrioventricular block (disease) · AV block · AV nodal block · AVB

Data availability: 2 ClinVar variants · 15 GWAS associations (16 studies) · 3 GenCC gene-disease records · 1 HPO phenotype.

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › heart conduction disease › atrioventricular block

Subtypes (4): first-degree atrioventricular block, second-degree atrioventricular block, third-degree atrioventricular block, congenital heart block

Genetics & variants

GWAS landscape

15 GWAS associations across 16 studies. Top hits map to 7 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs11191794	9e-23	SH3PXD2A	C	0.12
rs10428132	7e-21	SCN10A	T	0.11
chr3:38774832	1e-18		C	0.1
rs56005624	1e-18	CCDC141	T	0.14
rs72840788	6e-18	BAG3	G	0.13
chr2:179837282	6e-15		C	0.12
rs6785918	3e-13	SENP2	A	0.09
rs6801957	8e-13	SCN10A	?	0.82
rs1895583	9e-13	TBX5	A	0.09
chr3:185344539	2e-11		T	0.08
rs144629944	2e-08	NAP1L4P2 - SERPINA7P1	?
rs137860803	2e-07	FHIT	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475953	Verma A	2024	14,859	424,492	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477911	Verma A	2024	6,274	443,107	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477907	Verma A	2024	2,893	116,164	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480156	Verma A	2024	2,893	116,164	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436100	Zhou W	2018	2,125	380,919	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90477906	Verma A	2024	958	58,122	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477910	Verma A	2024	856	120,644	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480154	Verma A	2024	856	120,644	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90080003	Backman JD	2021	841	387,048	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083989	Backman JD	2021	841	387,048	Exome sequencing and analysis of 454,787 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	12

MAF distribution

Bucket	Variants
common (>=0.05)	10
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	2

Functional consequences

Consequence	Count
intron_variant	8
unknown	3
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs11191794	10	103756763	C>T	0.286	intron_variant	SH3PXD2A	9e-23	Tier 4: intronic/intergenic
rs10428132	3	38736063	T>A,C,G	0.363	intron_variant	SCN10A	7e-21	Tier 4: intronic/intergenic
chr3:38774832				0.405			1e-18	Tier 4: intronic/intergenic
rs56005624	2	178909907	T>G	0.133	intron_variant	CCDC141	1e-18	Tier 4: intronic/intergenic
rs72840788	10	119656173	G>A,T	0.165	intron_variant	BAG3	6e-18	Tier 4: intronic/intergenic
chr2:179837282				0.197			6e-15	Tier 4: intronic/intergenic
rs6785918	3	185612843	A>C,G,T	0.354	intron_variant	SENP2	3e-13	Tier 4: intronic/intergenic
rs6801957	3	38725824	T>A,C,G	0.05	intron_variant	SCN10A	8e-13	Tier 4: intronic/intergenic
rs1895583	12	114369080	A>C,G,T	0.292	intron_variant	TBX5	9e-13	Tier 4: intronic/intergenic
chr3:185344539				0.342			2e-11	Tier 4: intronic/intergenic
rs144629944	X	106504108	C>G,T		intergenic_variant	NAP1L4P2 - SERPINA7P1	2e-08	Tier 4: intronic/intergenic
rs137860803	3	61020602	A>C		intron_variant	FHIT	2e-07	Tier 4: intronic/intergenic

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

1 pathogenic/likely pathogenic, 1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
9385	NM_000335.5(SCN5A):c.4780G>A (p.Asp1594Asn)	SCN5A	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
9387	NM_000335.5(SCN5A):c.892G>A (p.Gly298Ser)	SCN5A	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 55 · Orphanet: 32 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
DES	Strong	Autosomal dominant	atrioventricular block	15
LMNA	Strong	Autosomal dominant	atrioventricular block	40

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
DES	Orphanet:154	Familial isolated dilated cardiomyopathy
DES	Orphanet:85146	Neurogenic scapuloperoneal syndrome, Kaeser type
DES	Orphanet:98909	Desminopathy
LMNA	Orphanet:154	Familial isolated dilated cardiomyopathy
LMNA	Orphanet:157973	Congenital muscular dystrophy due to LMNA mutation
LMNA	Orphanet:1662	Restrictive dermopathy
LMNA	Orphanet:168796	Heart-hand syndrome, Slovenian type
LMNA	Orphanet:2229	Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome
LMNA	Orphanet:2348	Familial partial lipodystrophy, Dunnigan type
LMNA	Orphanet:280365	Autosomal semi-dominant severe lipodystrophic laminopathy
LMNA	Orphanet:293888	Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
LMNA	Orphanet:293899	Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant
LMNA	Orphanet:293910	Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
LMNA	Orphanet:300751	Familial dilated cardiomyopathy with conduction defect due to LMNA mutation
LMNA	Orphanet:363618	LMNA-related cardiocutaneous progeria syndrome
LMNA	Orphanet:54260	Left ventricular noncompaction
LMNA	Orphanet:675396	Epithelioid hemangioma
LMNA	Orphanet:740	Hutchinson-Gilford progeria syndrome
LMNA	Orphanet:79084	Familial partial lipodystrophy, Köbberling type
LMNA	Orphanet:79474	Atypical Werner syndrome
LMNA	Orphanet:90153	Mandibuloacral dysplasia with type A lipodystrophy
LMNA	Orphanet:98853	Autosomal dominant Emery-Dreifuss muscular dystrophy
LMNA	Orphanet:98855	Autosomal recessive Emery-Dreifuss muscular dystrophy
LMNA	Orphanet:98856	Charcot-Marie-Tooth disease type 2B1
SCN5A	Orphanet:101016	Romano-Ward syndrome
SCN5A	Orphanet:130	Brugada syndrome
SCN5A	Orphanet:1344	Isolated atrial standstill
SCN5A	Orphanet:154	Familial isolated dilated cardiomyopathy
SCN5A	Orphanet:166282	Hereditary sick sinus syndrome
SCN5A	Orphanet:228140	Idiopathic ventricular fibrillation
SCN5A	Orphanet:334	Hereditary atrial fibrillation
SCN5A	Orphanet:871	Hereditary progressive cardiac conduction defect

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
DES	HGNC:2770	ENSG00000175084	P17661	Desmin	gencc
LMNA	HGNC:6636	ENSG00000160789	P02545	Prelamin-A/C	gencc
SCN5A	HGNC:10593	ENSG00000183873	Q14524	Sodium channel protein type 5 subunit alpha	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
DES	Desmin	Muscle-specific type III intermediate filament essential for proper muscular structure and function.
LMNA	Prelamin-A/C	Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane.
SCN5A	Sodium channel protein type 5 subunit alpha	Pore-forming subunit of Nav1.5, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Ion channel	1	37.2×	0.053
Other/Unknown	2	1.2×	0.587

Per-gene assignment

Symbol	Family	Druggable?	InterPro (top 3)
DES	Other/Unknown	no	Intermed_filament_DNA-bd, IF_conserved, IF_rod_dom
LMNA	Other/Unknown	no	Lamin_tail_dom, IF_conserved, Lamin_tail_dom_sf
SCN5A	Ion channel	yes	Na_channel_asu, Ion_trans_dom, Na_channel_a5su

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
apex of heart	2
gastrocnemius	1
saphenous vein	1
mucosa of stomach	1
nipple	1
skin of abdomen	1
cardiac ventricle	1
heart left ventricle	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
DES	280	broad	marker	apex of heart, saphenous vein, gastrocnemius
LMNA	295	ubiquitous	marker	nipple, mucosa of stomach, skin of abdomen
SCN5A	161	broad	yes	apex of heart, heart left ventricle, cardiac ventricle

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
LMNA	7,173
DES	2,486
SCN5A	2,090

Structural data

PDB: 2 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
LMNA	P02545	28
SCN5A	Q14524	16

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
DES	P17661	77.73

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 24. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Breakdown of the nuclear lamina	1	1268.9×	0.019	LMNA
Depolymerization of the Nuclear Lamina	1	253.8×	0.023	LMNA
Initiation of Nuclear Envelope (NE) Reformation	1	200.3×	0.023	LMNA
IRE1alpha activates chaperones	1	173.0×	0.023	LMNA
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models	1	173.0×	0.023	LMNA
Nuclear Envelope Breakdown	1	152.3×	0.023	LMNA
Interaction between L1 and Ankyrins	1	122.8×	0.023	SCN5A
Unfolded Protein Response (UPR)	1	119.0×	0.023	LMNA
Phase 0 - rapid depolarisation	1	115.3×	0.023	SCN5A
Striated Muscle Contraction	1	102.9×	0.023	DES
Oncogenic MAPK signaling	1	82.8×	0.026	LMNA
XBP1(S) activates chaperone genes	1	71.8×	0.028	LMNA
Signaling by BRAF and RAF1 fusions	1	56.8×	0.032	LMNA
Meiotic synapsis	1	47.0×	0.036	LMNA
L1CAM interactions	1	40.1×	0.040	SCN5A
Cardiac conduction	1	36.2×	0.041	SCN5A
Muscle contraction	1	25.7×	0.054	SCN5A
Diseases of signal transduction by growth factor receptors and second messengers	1	18.9×	0.069	LMNA
Axon guidance	1	15.1×	0.082	SCN5A
Nervous system development	1	14.3×	0.082	SCN5A
Cellular responses to stress	1	12.3×	0.091	LMNA
Cellular responses to stimuli	1	10.5×	0.101	LMNA
Developmental Biology	1	4.8×	0.202	SCN5A
Disease	1	4.4×	0.212	LMNA

GO biological processes by enrichment

GO term	Cohort genes	Fold	FDR	Sample cohort genes
nuclear envelope organization	2	660.9×	2e-04	DES, LMNA
bundle of His cell action potential	1	2808.7×	0.004	SCN5A
AV node cell to bundle of His cell communication	1	2808.7×	0.004	SCN5A
membrane depolarization during Purkinje myocyte cell action potential	1	1872.4×	0.004	SCN5A
membrane depolarization during bundle of His cell action potential	1	1872.4×	0.004	SCN5A
membrane depolarization during atrial cardiac muscle cell action potential	1	1872.4×	0.004	SCN5A
DNA double-strand break attachment to nuclear envelope	1	1872.4×	0.004	LMNA
establishment or maintenance of microtubule cytoskeleton polarity	1	1404.3×	0.004	LMNA
AV node cell action potential	1	1404.3×	0.004	SCN5A
nuclear pore localization	1	1123.5×	0.004	LMNA
membrane depolarization during AV node cell action potential	1	1123.5×	0.004	SCN5A
membrane depolarization during SA node cell action potential	1	1123.5×	0.004	SCN5A
regulation of ventricular cardiac muscle cell membrane depolarization	1	936.2×	0.004	SCN5A
negative regulation of mesenchymal cell proliferation	1	936.2×	0.004	LMNA
SA node cell action potential	1	936.2×	0.004	SCN5A
cardiac ventricle development	1	802.5×	0.004	SCN5A
response to denervation involved in regulation of muscle adaptation	1	802.5×	0.004	SCN5A
regulation of atrial cardiac muscle cell membrane repolarization	1	802.5×	0.004	SCN5A
brainstem development	1	702.2×	0.004	SCN5A
positive regulation of action potential	1	702.2×	0.004	SCN5A
skeletal muscle organ development	1	702.2×	0.004	DES
protein localization to nuclear envelope	1	702.2×	0.004	LMNA
regulation of protein localization to nucleus	1	702.2×	0.004	LMNA
regulation of atrial cardiac muscle cell membrane depolarization	1	624.1×	0.004	SCN5A
negative regulation of cardiac muscle hypertrophy in response to stress	1	624.1×	0.004	LMNA
membrane depolarization during action potential	1	561.7×	0.004	SCN5A
atrial cardiac muscle cell action potential	1	561.7×	0.004	SCN5A
ventricular cardiac muscle cell development	1	510.7×	0.005	LMNA
membrane depolarization during cardiac muscle cell action potential	1	468.1×	0.005	SCN5A
regulation of cardiac muscle cell contraction	1	374.5×	0.006	SCN5A

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dexamethasone	Phase 3 (in late-stage trials)
Human Immunoglobulin G	Phase 3 (in late-stage trials)

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 1

Druggability breadth: 2 of 3 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
LMNA	BEPRIDIL
SCN5A	BEPRIDIL

Top cohort targets by molecule count

Symbol	Molecules	Max phase
LMNA	823	4
SCN5A	108	4
DES	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
BEPRIDIL	4	LMNA, SCN5A
PHENYLBUTAZONE	4	LMNA
CEFOTAXIME SODIUM	4	LMNA
DIENESTROL	4	LMNA
IFOSFAMIDE	4	LMNA
PROGESTERONE	4	LMNA
CLOTRIMAZOLE	4	LMNA
DAPSONE	4	LMNA
AMINOCAPROIC ACID	4	LMNA
FLUCONAZOLE	4	LMNA
COLCHICINE	4	LMNA
NABUMETONE	4	LMNA
OXAPROZIN	4	LMNA
BUMETANIDE	4	LMNA
GLIPIZIDE	4	LMNA
BROMFENAC	4	LMNA
ROPIVACAINE	4	LMNA
TIZANIDINE	4	LMNA
METAXALONE	4	LMNA
CARBAMAZEPINE	4	LMNA, SCN5A
SALMETEROL XINAFOATE	4	LMNA
AMIODARONE HYDROCHLORIDE	4	LMNA
METHYL SALICYLATE	4	LMNA
DIBUCAINE	4	LMNA, SCN5A
PHENELZINE	4	LMNA
HYDROCORTISONE ACETATE	4	LMNA
BRETYLIUM TOSYLATE	4	LMNA
IMIPRAMINE	4	LMNA, SCN5A
FURAZOLIDONE	4	LMNA
DROPERIDOL	4	LMNA, SCN5A

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
SCN5A	594	Binding:380, Functional:98, ADMET:72, Toxicity:43, Unclassified:1
LMNA	12	Binding:9, Functional:3

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
SCN5A	594

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
BEPRIDIL	4	LMNA, SCN5A
PHENYLBUTAZONE	4	LMNA
CEFOTAXIME SODIUM	4	LMNA
DIENESTROL	4	LMNA
IFOSFAMIDE	4	LMNA
PROGESTERONE	4	LMNA
CLOTRIMAZOLE	4	LMNA
DAPSONE	4	LMNA
AMINOCAPROIC ACID	4	LMNA
FLUCONAZOLE	4	LMNA
COLCHICINE	4	LMNA
NABUMETONE	4	LMNA
OXAPROZIN	4	LMNA
BUMETANIDE	4	LMNA
GLIPIZIDE	4	LMNA
BROMFENAC	4	LMNA
ROPIVACAINE	4	LMNA
TIZANIDINE	4	LMNA
METAXALONE	4	LMNA
CARBAMAZEPINE	4	LMNA, SCN5A
SALMETEROL XINAFOATE	4	LMNA
AMIODARONE HYDROCHLORIDE	4	LMNA
METHYL SALICYLATE	4	LMNA
DIBUCAINE	4	LMNA, SCN5A
PHENELZINE	4	LMNA
HYDROCORTISONE ACETATE	4	LMNA
BRETYLIUM TOSYLATE	4	LMNA
IMIPRAMINE	4	LMNA, SCN5A
FURAZOLIDONE	4	LMNA
DROPERIDOL	4	LMNA, SCN5A

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	LMNA, SCN5A
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	DES

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
DES	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 72.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	66
PHASE4	4
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00292383	PHASE4	UNKNOWN	Ventricular Pacing Site Selection (V-PASS)
NCT00559143	PHASE4	WITHDRAWN	Biventricular Alternative Pacing
NCT01019213	PHASE4	COMPLETED	Acute and Chronic Effect of His-pacing in Consecutive Patients With AV-block
NCT01717469	PHASE4	UNKNOWN	Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias
NCT00925691	PHASE3	COMPLETED	Comparison of SEPTal and Apical Pacing Sites in PerManent Right Ventricular Pacing
NCT02462941	PHASE1	COMPLETED	Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart
NCT04624763	Not specified	ACTIVE_NOT_RECRUITING	Protection of Cardiac Function With Left Bundle Branch Pacing in Patients With Atrioventricular Block
NCT04926792	Not specified	ENROLLING_BY_INVITATION	Taiwan Registry for Leadless Pacemaker
NCT05585411	Not specified	RECRUITING	PReventive Effect Of Left Bundle Branch Area Pacing Versus righT vEntricular paCing on All Cause deaTh, Heart Failure Progression, and Ventricular dysSYNChrony in Patients With Substantial Ventricular Pacing (PROTECT-SYNC): Multicenter Prospective Randomized Controlled Trial
NCT05650658	Not specified	RECRUITING	Left vs Left Randomized Clinical Trial
NCT05774262	Not specified	RECRUITING	Pacemaker Implantation Versus Cardioneuroablation for Functional Atrioventricular Block
NCT05856799	Not specified	ACTIVE_NOT_RECRUITING	Danish Randomized Trial on Leadless vs Transvenous Pacing
NCT06023784	Not specified	NOT_YET_RECRUITING	The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
NCT06197503	Not specified	RECRUITING	Randomized Study of Physiological vs Right Ventricular Pacing in Patients With Normal Ventricular Function Post TAVI
NCT06324682	Not specified	RECRUITING	ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing
NCT06540079	Not specified	ACTIVE_NOT_RECRUITING	BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S
NCT06587672	Not specified	NOT_YET_RECRUITING	Factors Affecting Selection of Leadless Pacemaker and Atrioventricular Synchronous Pacing Status
NCT06707662	Not specified	RECRUITING	Left Septal Pacing or Left Bundle Branch Pacing to Avoid Left Ventricle Systolic Dysfunction
NCT06843135	Not specified	NOT_YET_RECRUITING	Synchrony in Cardiac Conduction: Assessing the Effects of Pacing on Cardiac Performance Through Magnetic Resonance Imaging and Advanced ECG-imaging
NCT06910059	Not specified	ACTIVE_NOT_RECRUITING	The CT-verified Data Collection Study to Investigate the Correlation Between the Leadless Pacemaker Tip Location and Echo, ECG
NCT07118358	Not specified	RECRUITING	BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07209852	Not specified	RECRUITING	Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up
NCT07236489	Not specified	RECRUITING	Trial Evaluating the Benefit of Left Bundle Branch Area Stimulation Compared With Conventional Pacing in Post-TAVI Atrioventricular Atrioventricular Block
NCT07250529	Not specified	RECRUITING	Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF
NCT07276490	Not specified	RECRUITING	Central Haemodynamics and Pacing for AV Block
NCT07279207	Not specified	NOT_YET_RECRUITING	PACE-AF: Prospective Analysis of Cardiac Electrostimulation and Atrial Fibrillation
NCT07279870	Not specified	RECRUITING	RandomIsed sTudy of Physiologic cArdiac stimuLation in patIents With Atrio-ventricular Conduction Disease
NCT07356505	Not specified	RECRUITING	Efficacy and Safety of Micra AV2 Transcatheter Pacing System
NCT07461935	Not specified	NOT_YET_RECRUITING	ALPs Single ChambEr New Device
NCT07464041	Not specified	RECRUITING	Left Bundle Branch Area Pacing Versus Right Ventricular Pacing in Atrioventricular Block With Preserved Ejection Fraction
NCT07469579	Not specified	NOT_YET_RECRUITING	ALPs Single ChambEr New Device Study
NCT07521800	Not specified	RECRUITING	Remote ECG Monitoring Post TAVI
NCT07608822	Not specified	NOT_YET_RECRUITING	BIO\|STREAM.CSP CLS
NCT00187278	Not specified	COMPLETED	Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization
NCT00228241	Not specified	UNKNOWN	Left Ventricular Function and Remodelling During Permanent Pacing
NCT00267098	Not specified	COMPLETED	Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
NCT00627328	Not specified	COMPLETED	The Atrial High Rate Episodes in Pacemaker Patients
NCT01441583	Not specified	COMPLETED	Ingenio Device Algorithm Study
NCT01798043	Not specified	TERMINATED	Impact of Septal Vs Apical Pacing on Right and Left Ventricular Performance
NCT01922518	Not specified	COMPLETED	Impact of Right Ventricular Pacing Determined by Electrocardiography

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ADENOSINE	4	1
METHOPRENE	2	1
CHEMBL606298	0	1

Cohort genes: DES, LMNA, SCN5A
Drugs: Adenosine